BIOCRYST PHARMACEUTICALS, INC. (BCRX) Operating income 2016–2025
BIOCRYST PHARMACEUTICALS, INC. (BCRX) annual operating income history from SEC filings — each fiscal year as reported.
$341.0MFY2025 · since FY2016: -$48.6M → $341.0M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | $341.0M | +13508.9% |
| FY2024 | -$2.5M | +97.5% |
| FY2023 | -$103.7M | +30.1% |
| FY2022 | -$148.4M | +16.5% |
| FY2021 | -$177.7M | -1.7% |
| FY2020 | -$174.8M | -75.7% |
| FY2019 | -$99.5M | -5.6% |
| FY2018 | -$94.2M | -64.1% |
| FY2017 | -$57.4M | -18.1% |
| FY2016 | -$48.6M | — |
Source: SEC XBRL filings · For reference only · Not investment advice
More BCRX financial trends
BCRX RevenueBCRX Net incomeBCRX Net marginBCRX Gross profitBCRX Gross marginBCRX Operating marginBCRX Operating cash flowBCRX Free cash flowBCRX Capital expendituresBCRX Return on equityBCRX Stock buybacksBCRX Dividends paidBCRX Total assetsBCRX Total liabilitiesBCRX Shareholders’ equityBCRX overview →